Interim Chief Executive Officer and Chairman of the Board
Ron Tilles has been on the Board of Directors of Turing Pharmaceuticals since the company launched late 2014. Mr. Tilles started his career at Merrill Lynch in 1985, then worked at several other securities firm including Nikko and Yamaichi Securities. He is a well-respected financial services executive, having made investments in a number of public and private companies in the pharmaceutical and medical device industries over the last 20 years. Mr. Tilles was one of the founders of Retrophin, Inc. (Nasdaq: RTRX). He earned his undergraduate degree from Middlebury College in Vermont and his Masters of Business Administration from Columbia University in New York.
Chief Commercial Officer
Nancy Retzlaff is the Chief Commercial Officer at Turing Pharmaceuticals. Prior to joining Turing, Ms. Retzlaff was the VP of Global Marketing / Commercial at Mesoblast Inc. in New York City. Previously with Pfizer, she held the lead regional commercial role in Japan, Australia, Canada and Korea. Also with Pfizer she held a global role in Neurosciences. In addition to her time at Mesoblast Inc. and Pfizer, Ms. Retzlaff has worked at Schering-Plough and Bayer. Ms. Retzlaff received a Bachelor of Commerce; Marketing & General Business at the University of Saskatchewan.
President of Research and Development
Dr. Eliseo Salinas is President of Research and Development at Turing Pharmaceuticals. During his 24 year career in the Pharmaceutical Industry he has conducted numerous pre-clinical and clinical programs targeting multiple disease areas. 15 drug programs under Dr. Salinas' direction led to drug approvals by the Food and Drug Administration and international regulatory bodies for Central Nervous System, Gastrointestinal and Renal disorders. A native of Argentina, Dr. Salinas received his medical degree from the University of Buenos Aires, performed his residency in psychiatry at the Clinique des Maladies Mentales et de l´Encéphale and his master's in pharmacology at the Pierre and Marie Curie University, both in Paris. Dr. Salinas served on the faculty of Rene Descartes University in Paris and has published scientific papers in the area of psychopharmacology and methodology of research.
Vice President, Regulatory Affairs
Nicholas Pelliccione, Ph.D. is the Vice President of Regulatory Affairs at Turing Pharmaceuticals AG. Dr. Pelliccione has been a leader in the areas of global Regulatory Affairs and Quality Assurance for almost 30 years. He has been responsible for teams working in the clinical, preclinical and CMC regulatory development of new drugs in the oncology, endocrine/metabolic, anti-infectives, cytokines, and cardiovascular therapy areas, leading to a number of approvals. He has long standing experience working with both small and large pharma companies providing strategic and operational leadership in regulatory and quality matters as they relate to FDA and other health authorities. Dr. Pelliccione, a lifelong Brooklyn resident, received a BS in Chemistry from Polytechnic Institute of Brooklyn and a Ph.D. in Biochemistry from Mount Sinai School of Medicine (CUNY).
Chief People Officer
Peter Myall is the Chief People Officer, at Turing Pharmaceuticals. Mr. Myall has over 20 years of human resource management experience in a range of industries. He joined Turing in January 2015 from GlaxoSmithKline where he held a global HR role in their vaccines division. He also previous worked in GSK's consumer healthcare business. Prior to GSK he spent time in the UK health service and the transportation industry. Mr. Myall currently resides in New York City and originates from the UK. He has also previously worked in Belgium. Mr. Myall has an MBA from the Open Business School.
Head of Human Resources Switzerland/Europe
Erika joined Turing as Head HR Switzerland/Europe based in Baar reporting to Head HR. Erika was working in the financial industry for Bank Julius Bär, UBS Investment Bank Switzerland, UBS Global Asset Management, Zurich Insurance and also for the Federal Office of Meteorology and Climatology etc. She also was working with a lot of Investments analysts of the Pharma industry. She speaks excellent English, Spanish, German and French. Erika has 25 years international experience in HR and holds a Master in Human Resources of ZHAW, Zurich.
Head of European Business Development and Operations
Ged Yardy is Head of European Business Development and Operations at Turing Pharmaceuticals AG located in Switzerland. During his 20 year career in the industry Mr. Yardy has held different manager roles in Business Development and Operations. Before starting at Turing he was interim Director of BD for Norgine Pharma and prior to that Director CNS Research & Early Development Operations for Roche and Director BD & Alliance Management for Actelion. Mr. Yardy became a member of a number of intercompany joint supervisory Boards with Merck, Roche, GSK, BSP and Actelion. Mr. Yardy holds an MBA from University of Bradford, has completed ECPM studies at University of Basel and is a chartered Eur Ing.